All News
Filter News
Found 73,709 articles
-
Pet Diabetes Care Market: Rise in Prevalence of Diabetes in Pet Animals to drive the Market
9/21/2020
Diabetic dogs and cats can live long and healthy lives with proper management and veterinary care.
-
Microscopy Devices Market: Optical Microscopy Dominates the Market, Followed by Electron Microscopy
9/21/2020
Transparency Market Research has published a new report titled, “Global Microscopy Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.
-
In Vitro Diagnostics Market: Rise in Prevalence of Chronic Ailments to Drive Growth
9/21/2020
The global in-vitro diagnostics market is predicted to experience brisk development in the coming years, according to a Transparency Market Research report.
-
Healthcare ERP Market: Trends, Opportunities and Regional Outlook
9/21/2020
Over the past couple of decades, enterprise resource planning systems and associated technologies have garnered considerable traction across diverse industries beginning with the manufacturing sector.
-
Gynecological Devices Market: Efforts of Global Health Organizations for Women Health a Boon for Market
9/21/2020
The global gynecological devices market is treading a growth path on the back of rising incidence of gynecological disorders such as fibroids and cervical cancer.
-
Fungal Infection Drugs Market: Rise in prevalence of chronic diseases is projected to drive the market
9/21/2020
A fungal infection is also known as mycosis. It is a skin disease caused by a fungus. There are a million species of fungi.
-
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
9/20/2020
Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor)
-
Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer
9/20/2020
60% ORR in patients previously treated with vandetanib or cabozantinib, and 74% ORR in treatment-naïve patients
-
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
9/20/2020
Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”)
-
Statement from the Chief Public Health Officer of Canada on September 20, 2020
9/20/2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement
-
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
9/20/2020
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition
-
Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine
9/20/2020
Confirmed and Durable Anticancer Activity in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients From Phase 1 Trial
-
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
9/20/2020
New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy
-
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial
9/20/2020
LYNPARZA is the Only PARP Inhibitor to Demonstrate Improved Overall Survival in Metastatic Castration-Resistant Prostate Cancer
-
Hospital Disinfectant Products Market | Exclusive Report Study on Current Scenario of Market
9/20/2020
Cleaning and disinfection of surfaces is a key part of disinfection routines in hospitals and clinics around the world.
-
Viral Disease Diagnosis Market | Latest Technological Innovations during COVID-19 Drive the Growth of Market
9/20/2020
As COVID-19 continues to affect the global populace, the diagnosis of the novel coronavirus for speedy recovery has become the need of the hour.
-
Recombinant Vaccines Market | Covid-19 Epidemic Opens New Avenues for Market Growth
9/20/2020
Recombinant vaccine is one of the important tools today in healthcare industry.
-
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
9/19/2020
Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone
-
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
9/19/2020
Cabometyx® in combination with Opdivo® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile
-
Statement from the Chief Public Health Officer of Canada on September 19, 2020
9/19/2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement